Cargando…

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials

The randomized, double‐blind, cardiovascular outcomes trials LEADER (NCT01179048) and SUSTAIN 6 (NCT01720446) showed cardiovascular risk reduction in patients with type 2 diabetes treated with liraglutide and semaglutide, respectively, compared with placebo. This post hoc analysis examined the impac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verma, Subodh, Bain, Stephen C., Honoré, Julie Broe, F. E. Mann, Johannes, A. Nauck, Michael, E. Pratley, Richard, Rasmussen, Søren, Sejersten Ripa, Maria, Zinman, Bernard, Buse, John B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689837/ https://www.ncbi.nlm.nih.gov/pubmed/32643857 http://dx.doi.org/10.1111/dom.14140

Ejemplares similares

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2019)

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
por: Leiter, Lawrence A., et al.
Publicado: (2020)

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
por: Verma, Subodh, et al.
Publicado: (2021)

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
por: Verma, Subodh, et al.
Publicado: (2020)

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
por: Buse, John B., et al.
Publicado: (2020)

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
por: Shaman, Ahmed M., et al.
Publicado: (2021)

Liraglutide and Glycaemic Outcomes in the LEADER Trial
por: Zinman, Bernard, et al.
Publicado: (2018)

Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial
por: Tack, Cees J., et al.
Publicado: (2019)

Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial
por: Nauck, Michael A, et al.
Publicado: (2018)

Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials
por: Kahkoska, Anna R., et al.
Publicado: (2020)

LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial
por: Steinberg, William M., et al.
Publicado: (2014)

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
por: Mosenzon, Ofri, et al.
Publicado: (2020)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
por: Verma, Subodh, et al.
Publicado: (2022)

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
por: Daniels, G H, et al.
Publicado: (2015)

Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920
por: Nauck, Michael A., et al.
Publicado: (2020)

Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial
por: Nauck, Michael A., et al.
Publicado: (2018)

Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
por: Crowley, Matthew J., et al.
Publicado: (2020)

Cardiac Microvascular Dysfunction in Women Living With HIV Is Associated With Cytomegalovirus Immunoglobulin G
por: Knudsen, Andreas, et al.
Publicado: (2018)

Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
por: Strain, W. David, et al.
Publicado: (2022)

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
por: Mann, Johannes F. E., et al.
Publicado: (2021)

LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial
por: Petrie, John R., et al.
Publicado: (2016)

Imaging Atherosclerosis with Hybrid Positron Emission Tomography/Magnetic Resonance Imaging
por: Ripa, Rasmus Sejersten, et al.
Publicado: (2015)

RedeAmericas: building research capacity in young leaders for sustainable growth in community mental health services in Latin America
por: Yang, L., et al.
Publicado: (2017)

Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes
por: Buse, John B., et al.
Publicado: (2021)

Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME
por: Verma, Subodh, et al.
Publicado: (2020)

Non-Invasive Imaging for Subclinical Coronary Atherosclerosis in Patients with Peripheral Artery Disease
por: Ripa, Rasmus Sejersten, et al.
Publicado: (2014)

Clinicians as Leaders: Impact and Challenges
por: Khan, Rehan Nasir, et al.
Publicado: (2022)

The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials
por: Zobel, Emilie H., et al.
Publicado: (2021)

Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes
por: Nunez Lopez, Yury O., et al.
Publicado: (2018)

Vaccine Champions Training Program: Empowering Community Leaders to Advocate for COVID-19 Vaccines
por: Kaufman, Jessica, et al.
Publicado: (2022)

Coronary Venous Pressure and Microvascular Hemodynamics in Patients With Microvascular Angina: A Randomized Clinical Trial
por: Ullrich, Helen, et al.
Publicado: (2023)

Resources that Help Sustain Environmental Volunteer Activist Leaders
por: Gulliver, Robyn E., et al.
Publicado: (2023)

Worst lead ST deviation and resolution of ST elevation at one hour for prediction of myocardial salvage, infarct size, and microvascular obstruction in patients with ST‐elevation myocardial infarction treated with primary percutaneous coronary intervention
por: Stensjøen, Anne Line, et al.
Publicado: (2020)

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
por: Verma, Subodh, et al.
Publicado: (2018)

Psychiatric Nurse Practitioners as Leaders in Behavioral Health Integration
por: Birch, Kara, et al.
Publicado: (2021)

Sustainable career and employability of student leaders in China
por: Bai, Bin, et al.
Publicado: (2022)

LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ
por: Rutten, Guy E. H. M., et al.
Publicado: (2016)

Editorial: Advanced Cardiovascular Imaging in Diabetes
por: Schick, Fritz, et al.
Publicado: (2022)

Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11)
por: Amod, Aslam, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5e42iuh6t4c89n4lu9bv0s4d4n